Subscribe to Newsletter
Business & Regulation Drug Delivery, Formulation, Standards & Regulation

Accelerating the deformulation workflow for oral solid dosage forms


Oral Solid Dosage (OSD) forms still represent a significant share of the pharmaceutical market. As a result, they remain an important target for generic product developers. OSD products tend to be viewed as simpler to reverse engineer compared to those with more complex delivery mechanisms, such as Orally Inhaled and Nasal Drug Products (OINDPs). However, deformulation - the unpicking and rationalization of those characteristics of a Reference Listed Drug (RLD) that deliver its performance - still requires significant effort, especially when considering modified or sustained release OSD products. In addition, the development of a new generic can be an intensely competitive process, with multiple companies chasing the opportunity to be first to file in the US in order to claim a highly valuable period of exclusivity. Optimizing the deformulation workflow to accelerate submission and secure regulatory approval is therefore an important goal.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine